Biologics in food allergy: up-to-date

References

• Boyano-Martínez T, García-Ara C, Pedrosa M, et al. Accidental allergic reactions in children allergic to cow’s milk proteins. J Allergy Clin Immunol. 2009;123(4):883–888.
   PubMed Web of Science ®Google Scholar
• Marrs T, Lack G. Why do few food-allergic adolescents treat anaphylaxis with adrenaline?–reviewing a pressing issue. Pediatr Allergy Immunol. 2013;24(3):222–229.
   PubMed Web of Science ®Google Scholar
• Wang J, Sicherer SH, Section on allergy and immunology. Guidance on completing a written allergy and anaphylaxis emergency plan. Pediatrics. 2017;139:3.
   Web of Science ®Google Scholar
• Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: igE-mediated food allergy. Allergy. 2018;73(4):799–815.
   PubMed Web of Science ®Google Scholar
• Scurlock AM. Oral and sublingual immunotherapy for treatment of IgE-mediated food allergy. Clin Rev Allergy Immunol. 2018;55(2):139–152.
   PubMed Web of Science ®Google Scholar
• Passanisi S, Lombardo F, Crisafulli G, et al. Novel diagnostic techniques and therapeutic strategies for IgE-mediated food allergy. Allergy Asthma Proc. 2021;42(2):124–130.
   PubMed Web of Science ®Google Scholar
• Arasi S, Castagnoli R, Pajno GB. Oral immunotherapy in pediatrics. Pediatr Allergy Immunol. 2020;31(Suppl 24):51–53.
   PubMed Web of Science ®Google Scholar
• Labrosse R, Graham F, Des Roches A, et al. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65(3):189–199.
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72(8):1133–1147.
   PubMed Web of Science ®Google Scholar
• Long A, Borro M, Sampath V, et al. New developments in non-allergen-specific therapy for the treatment of food allergy. Curr Allergy Asthma Rep. 2020;20(1):3.
   PubMed Web of Science ®Google Scholar
• De Martinis M, Sirufo MM, Viscido A, et al. Food allergy insights: a changing landscape. Arch Immunol Ther Exp (Warsz). 2020;68(2):8.
   PubMed Web of Science ®Google Scholar
• Ali A, Tan H, Kaiko GE. Role of the intestinal epithelium and its interaction with the microbiota in food allergy. Front Immunol. 2020;11:604054.
   PubMed Web of Science ®Google Scholar
• Jappe U, Schwager C, Schromm AB, et al. Lipophilic allergens, different modes of allergen-lipid interaction and their impact on asthma and allergy. Front Immunol. 2019;10:122.
   PubMed Web of Science ®Google Scholar
• Chinthrajah RS, Tupa D, Prince BT, et al. Diagnosis of food allergy. Pediatr Clin North Am. 2015;62(6):1393–1408.
   PubMed Web of Science ®Google Scholar
• Lee J-B, Chen C-Y, Liu B, et al. IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy. J Allergy Clin Immunol. 2016;137(4):1216–1225.
   PubMed Web of Science ®Google Scholar
• Forbes EE, Groschwitz K, Abonia JP, et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008;205(4):897–913. .
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature. 2002;3(7):673–680.
   Web of Science ®Google Scholar
• Kitajima M, Lee H-C, Nakayama T, et al. TSLP enhances the function of helper type 2 cells. Eur J Immunol. 2011;41(7):1862–1871.
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008;181(7):4780–4790.
   PubMed Web of Science ®Google Scholar
• Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med. 2003;197(6):687–701.
   PubMed Web of Science ®Google Scholar
• Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet. 2002;70(1):230–236.
   PubMed Web of Science ®Google Scholar
• Noval Rivas M, Burton OT, Wise P, et al. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015;42(3):512–523.
   PubMed Web of Science ®Google Scholar
• Noval Rivas M, Burton OT, Oettgen HC, et al. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138(3):801–811.
   PubMed Web of Science ®Google Scholar
• Sampath V, Sindher SB, Alvarez Pinzon AM, et al. Can food allergy be cured? What are the future prospects? Allergy. 2020;75(6):1316–1326.
   PubMed Web of Science ®Google Scholar
• Freeland DMH, Manohar M, Andorf S, et al. Oral immunotherapy for food allergy. Semin Immunol. 2017;30:36–44.
   PubMed Web of Science ®Google Scholar
• J-m L-C, Galand C, Kam C, et al. Mechanical skin injury promotes food anaphylaxis by driving intestinal mast cell expansion. Immunity. 2019;50(5):1262–1275.
   PubMed Web of Science ®Google Scholar
• Johnston LK, Hsu C-L, Krier-Burris RA, et al. IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis. J Immunol. 2016;197(9):3445–3453.
   PubMed Web of Science ®Google Scholar
• Pajno GB, Passanisi S, Valenzise M, et al. The evolution of allergen specific immunotherapy: the near and far future. Pediatr Allergy Immunol. 2020;31(S26):11–13.
   Web of Science ®Google Scholar
• Leung DYM, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986–993.
   PubMed Web of Science ®Google Scholar
• MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158(3):1438–1445.
   PubMed Web of Science ®Google Scholar
• Saini SS, MacGlashan DW, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162(9):5624–5630.
   PubMed Web of Science ®Google Scholar
• Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J. 2014;7(1):17.
   PubMedGoogle Scholar
• Pajno GB, Castagnoli R, Arasi S, et al. Pediatric use of omalizumab for allergic asthma. Expert Opin Biol Ther. 2020;20(7):695–703.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Passanisi S, Arasi S, Caminiti L, et al. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33(4):e13489.
   PubMed Web of Science ®Google Scholar
• Crisafulli G, Caminiti L, Chiera F, et al. Omalizumab in children with severe allergic disease: a case series. Ital J Pediatr. 2019;45(1):13.
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–1624.
   PubMed Web of Science ®Google Scholar
• Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10.e1.
   PubMed Web of Science ®Google Scholar
• Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7.
   PubMed Web of Science ®Google Scholar
• Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, et al. Anti-IgE-assisted desensitization to egg and cow’s milk in patients refractory to conventional oral immunotherapy. Pediatr Allergy Immunol. 2016;27(5):544–546.
   PubMed Web of Science ®Google Scholar
• Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–1110.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow’s milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453.
   PubMed Web of Science ®Google Scholar
• Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy. 2017;47(4):540–550.
   PubMed Web of Science ®Google Scholar
• MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–881.
   PubMed Web of Science ®Google Scholar
• Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94.
   PubMed Web of Science ®Google Scholar
• Langlois A, Lavergne M-H, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy Asthma Clin Immunol. 2020;16(1):25.
   PubMed Web of Science ®Google Scholar
• Andorf S, Manohar M, Dominguez T, et al. Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab. Allergy Asthma Clin Immunol. 2017;13(1):51.
   PubMed Web of Science ®Google Scholar
• Andorf S, Manohar M, Dominguez T, et al. Feasibility of sustained response through long-term dosing in food allergy immunotherapy. Allergy Asthma Clin Immunol. 2017;13(1):52.
   PubMed Web of Science ®Google Scholar
• Andorf S, Purington N, Kumar D, et al. A Phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine. 2019;7:27–38.
   PubMedGoogle Scholar
• Lafuente I, Mazon A, Nieto M, et al. Possible recurrence of symptoms after discontinuation of omalizumab in anti‐IgE‐assisted desensitization to egg. Pediatr Allergy Immunol. 2014;25(7):717–719.
   PubMed Web of Science ®Google Scholar
• Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients. J Allergy Clin Immunol. 2020;147(1):S0091-6749(20)31319–1.
   PubMed Web of Science ®Google Scholar
• Mizuma H, Tanaka A, Uchida Y, et al. Influence of omalizumab on allergen-specific IgE in patients with adult asthma. Int Arch Allergy Immunol. 2015;168(3):165–172.
   PubMed Web of Science ®Google Scholar
• Dahdah L, Ceccarelli S, Amendola S, et al. IgE immunoadsorption knocks down the risk of food-related anaphylaxis. Pediatrics. 2015;136(6):e1617–1620.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Nordvall L, Johansson SGO, et al. Successful management of severe cow’s milk allergy with omalizumab treatment and CD-sens monitoring. Asia Pac Allergy. 2014;4(4):257–260.
   PubMedGoogle Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Jensen RK, Jabs F, Miehe M, et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy. 2020;75(8):1956–1965.
   PubMed Web of Science ®Google Scholar
• Sastre J, Dávila DI. Dupilumab: a new paradigm for the treatment of allergic diseases. Journal of Investigational Allergology and Clinical Immunology. 2018;28(3):139–150.
   PubMed Web of Science ®Google Scholar
• May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015;75(1):89–116.
   PubMed Web of Science ®Google Scholar
• Gour N, Wills-Karp MIL-4. and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68–78.
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5–14.
   PubMed Web of Science ®Google Scholar
• Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccines Immunother. 2019;15(9):2129–2139.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Dupilumab (Dupixent) for asthma. JAMA. 2019. 321(10):1000–1001. 12.
   PubMed Web of Science ®Google Scholar
• Abdel-Gadir A, Schneider L, Casini A, et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825–836.
   PubMed Web of Science ®Google Scholar
• Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract. 2019;7(2):673–674.
   PubMed Web of Science ®Google Scholar
• Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to AR101 (Peanut Oral Immunotherapy). ClinicalTrials.gov Identifier: NCT03682770. Available from: https://clinicaltrials.gov/ct2/show/NCT03682770
   Google Scholar
• Study to evaluate dupilumab monotherapy in pediatric patients with peanut allergy. ClinicalTrials.gov Identifier:NCT03793608. Available from: https://clinicaltrials.gov/ct2/show/NCT03793608
   Google Scholar
• Clinical study using biologics to improve multi OIT outcomes. ClinicalTrials.gov Identifier: NCT03679676. Available from: https://clinicaltrials.gov/ct2/show/NCT03679676
   Google Scholar
• Varricchi G, Canonica GW. The role of interleukin 5 in asthma. Expert Rev Clin Immunol. 2016;12(9):903–905.
   PubMed Web of Science ®Google Scholar
• Stirling RG, Van Rensen EL, Barnes PJ, et al. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1403–1409.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.
   PubMed Web of Science ®Google Scholar
• Rossjohn J, McKinstry WJ, Woodcock JM, et al. Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist. Blood. 2000;95(8):2491–2498.
   PubMed Web of Science ®Google Scholar
• Broughton SE, Dhagat U, Hercus TR, et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012;250(1):277–302.
   PubMed Web of Science ®Google Scholar
• Olivieri B, Tinazzi E, Caminati M, et al. Biologics for the treatment of allergic conditions: eosinophil disorders. Immunol Allergy Clin North Am. 2020;40(4):649–665.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Li R, McGowan EC. The role of food allergy in eosinophilic esophagitis. J Asthma Allergy. 2020;13:679–688.
   PubMed Web of Science ®Google Scholar
• Khodoun MV, Tomar S, Tocker JE, et al. Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33. J Allergy Clin Immunol. 2018;141(1):171–179.e1.
   PubMed Web of Science ®Google Scholar
• Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386(1):181–185.
   PubMed Web of Science ®Google Scholar
• Allinne J, Scott G, Lim WK, et al. IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019;144(6):1624–1637.
   PubMed Web of Science ®Google Scholar
• Chen Y-L, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):515.
   Web of Science ®Google Scholar
• Peng G, Mu Z, Cui L, et al. Anti-IL-33 antibody has a therapeutic effect in an atopic dermatitis murine model induced by 2, 4-dinitrochlorobenzene. Inflammation. 2018;41(1):154–163.
   PubMed Web of Science ®Google Scholar
• Kim YH, Yang TY, Park C-S, et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy. 2012;67(2):183–190.
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK, Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976.
   PubMed Web of Science ®Google Scholar
• Di Salvo E, Ventura-Spagnolo E, Casciaro M. IL-33/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. 2018 Mar 11;2018:3858032.
   PubMed Web of Science ®Google Scholar
• Londei M, Kenney B, Los G, et al. A Phase 1 study of ANB020, an anti-IL-33 monoclonal antibody in healthy volunteers. J Allergy Clin Immunol. 2017;139(2):AB73.
   Web of Science ®Google Scholar
• Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019;4(22):22.
   Web of Science ®Google Scholar
• Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931–940.
   PubMedGoogle Scholar
• Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet L-P, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar